gemcitabine has been researched along with amd 070 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Koide, S; Matsuo, Y; Morimoto, M; Saito, K; Sato, T; Shamoto, T; Takahashi, H; Takeyama, H; Tsuboi, K | 1 |
2 other study(ies) available for gemcitabine and amd 070
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Topics: Aminoquinolines; Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Butylamines; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Female; Fibroblasts; Gemcitabine; Heterocyclic Compounds, 1-Ring; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, CXCR4; Stromal Cells; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |